Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (12)

2024

  1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  2. Difficulties on the access to innovative targeted therapies for lung cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612

2023

  1. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

2021

  1. Follow-up care over 12months of patients with prostate cancer in Spain A multicenter prospective cohort study

    Medicine (United States), Vol. 100, Núm. 47

  2. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

2018

  1. LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii38

2017

  1. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

    The Lancet Respiratory Medicine, Vol. 5, Núm. 5, pp. 435-444

  2. Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions

    Annals of Oncology, Vol. 28, Núm. 9, pp. 2248-2255

2015

  1. Functional FLT1 genetic variation is a prognostic factor for recurrence in Stage I-III non-small-cell lung cancer

    Journal of Thoracic Oncology, Vol. 10, Núm. 7, pp. 1067-1075

2014

  1. Bladder cancer index: Cross-cultural adaptation into Spanish and psychometric evaluation

    Health and Quality of Life Outcomes, Vol. 12, Núm. 1

2009

  1. Screening for epidermal growth factor receptor mutations in lung cancer

    New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967

  2. Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

    Clinical and Translational Oncology, Vol. 11, Núm. 11, pp. 727-736